310442-40-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester is used as a research compound for its potential applications in the development of new pharmaceuticals. Its unique structure and functional groups make it a candidate for further investigation in drug discovery processes.
Used in Chemical Synthesis:
4-Chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester is used as an intermediate compound in the synthesis of more complex molecules. Its presence in the pyrrolo[2,1-f][1,2,4]triazines class suggests that it may be involved in the creation of compounds with diverse applications and biological activities.

Upstream product

• 310431-29-9 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 
• 623-43-8 methyl crotonate 
• 3780-42-5 dimethyl 3-methyl-1H-pyrrole-2,4-dicarboxylate 
• 40318-15-8 methyl 4-methyl-1H-pyrrole-3-carboxylate 
• 310431-26-6 dimethyl 1-amino-3-methyl-1H-pyrrole-2,4-dicarboxylate 
• 623-43-8 crotonic acid methyl ester 

Downstream Products

• 310442-32-1 4-[(3-Hydroxy-4-methylphenyl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 
• 310442-33-2 4-[(3-Hydroxy-4-methylphenyl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 310442-42-3 4-[(3-Carboxyphenyl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic Acid Methyl Ester 
• 310442-44-5 4-[[3-Hydroxy-4-[(phenylsulfonyl)amino]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 
• 310444-81-6 4-phenoxy-5-methyl-6-carbomethoxypyrrolo[2,1-f][1,2,4]triazine 
• 310442-47-8 4-[[3-(Hydroxysulfonyl)phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 
• 1005196-65-5 methyl 4-(2-methyl-5-(methoxycarbamoyl)phenylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 1005196-67-7 methyl 4-(2-methyl-5-(ethoxycarbamoyl)phenylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 1005196-64-4 methyl 5-methyl-4-(2-methyl-5-(methylcarbamoyl)phenylamino)pyrrolo[1,2-f][1,2,4]triazine-6-carboxylate 
• 1005196-66-6 C₁₇H₁₇N₅O₃ 
• 427877-58-5 C₁₉H₂₁N₅O₃ 
• 1005196-62-2 4-((5-(methoxycarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 

Relevant academic research and scientific papers

PYRROLOTRIAZINE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Synthesis of carbon-11-labeled 4-(phenylamino)-pyrrolo[2,1-f][1,2,4] triazine derivatives as new potential PET tracers for imaging of p38α mitogen-activated protein kinase

The reference standards methyl 4-(2-methyl-5-(methoxycarbamoyl)phenylamino) -5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate (10a), methyl 4-(2-methyl-5-(ethoxycarbamoyl)phenylamino)-5-methylpyrrolo[2,1-f][1,2,4] triazine-6-carboxylate (10b) and corre

Pyrrolotriazine inhibitors of kinases

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors

A versatile synthesis of the suitably functionalized pyrrolo[2,1-f][1,2,4] triazine nucleus is described. SAR at the C-5 and C-6 positions of the 4-(3-hydroxy-4-methylphenylamino)pyrrolo[2,1-f][1,2,4]triazine template led to compounds with good in vitro potency against VEGFR-2 kinase. Glucuronidation of the phenol group is mitigated by incorporation of a basic amino group on the C-6 side chain of the pyrrolotriazine nucleus.

Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I): 1or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, or NH2, preferably methyl, and X, R1 through R6, and Z are as described in the specification. Advantageously the groups —ZR4R5 taken together comprise an —NH-substituted aryl.